Search results
Showing 1 to 7 of 7 results for lorlatinib
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
Evidence-based recommendations on lorlatinib (Lorviqua) for untreated ALK-positive advanced non-small-cell lung cancer in adults.
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]
In development [GID-TA11570] Expected publication date: 24 July 2025
In development [GID-TA11289] Expected publication date: TBC
Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor.
Hypophosphatasia (paediatric-onset) - asfotase alfa TA10812 Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer...
Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.